26
If statin intolerance is an issue, consideration should be given
to the use of alternate statin regimens such as low intensity
statin therapy or non-daily moderate intensity statin therapy,
low dose statin combination therapy with ezetimibe, bile
acid sequestrants, or niacin, or non-statin monotherapy (i.e.,
ezetimibe or bile acid sequestrant) or their combination, with
a goal of ≥30% reduction in LDL-C.
B Moderate
Chart 8. Older Patients (cont'd)
Recommendations
Strength Quality
Special Populations
Ethnic Groups
Chart 9. Hispanics/Latinos
Recommendations
Strength Quality
In general, patients of Hispanic/Latino ethnicity should be
treated according to the NLA Recommendations for Patient-
Centered Management of Dyslipidemia – Part 1 with the
following special considerations.
A High
Clinicians should be aware that Hispanics/Latinos in the
United States are a diverse population group tracing their
ancestry to Mexico, the Caribbean (Puerto Rico, Cuba, and
the Dominican Republic), Central America (El Salvador and
Guatemala), and South America. ASCVD risk factor burden
varies widely among individuals of Hispanic/Latino descent,
depending on their country of origin.
A High
Hispanics/Latinos tend to have a greater prevalence of high
TG and low HDL-C than non-Hispanic whites (NHWs),
leading to higher levels of non-HDL-C, and an increased
likelihood for discordance between LDL-C and non-
HDL-C concentrations. LDL-C levels tend to be higher in
Hispanic men compared with NHW men.
A Moderate
Hispanics/Latinos have higher prevalence of type 2 diabetes
mellitus, obesity, and metabolic syndrome compared to
NHWs, particularly among women.
A Moderate
Some cardiovascular risk equations (e.g., Framingham
equations) may overestimate risk in Hispanic/Latino
individuals.
B Moderate
